PROCEPT BioRobotics Stock News

SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) against certain of its officers and directors for alleged breaches of fiduciary duty.

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“PROCEPT” or the “Company”) (NASDAQ: PRCT) on behalf of all purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026 (the “Class Period”).

A securities fraud class action lawsuit has been filed on behalf of Procept investors after its stock plummeted 18% because Procept allegedly artificially inflated its financial performance via an extensive discount program that incentivized customers to place bulk orders. NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP  announces that a class acti...

SAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2026.

SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation® therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablatio...

SAN JOSE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the American Urological Association (AUA) Guidelines for the management of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), which strengthen the recommendation for Aquablation therapy (Robotic Waterjet Treatment) as a surgical treatme...

SAN JOSE, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at three upcoming investor conferences in May and June.